On Sept. 15, 2021, the U.S. Department of Defense in coordination with the Department of Health and Human Services awarded two contract modifications totaling $3.2 billion to Regeneron Pharmaceuticals, Inc. and Eli Lilly and Company to purchase additional doses of monoclonal antibodies to block the infectivity of SARS-CoV-2, the virus that causes COVID-19.